The law firm of Federman & Sherwood has launched an investigation of
Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (“Provectus” or “the
Company”) for possible violations of Sections 10(b) and 20(a) of the
Securities Exchange Act of 1934 and/or breaches of fiduciary duty by the
Company’s officers and directors.
Federman & Sherwood’s investigation surrounds whether information
contained in an analyst’s May 21, 2014 article published in Seeking
Alpha is true as alleged. More specifically, it is alleged that the
Company failed to commence a Phase 3 randomized, controlled trial of
PV-10 after completing its Phase 2 study in 2010. This same article also
alleged that Provectus is tied to a stock promotion firm whose
recommendations were recently halted by the Securities and Exchange
Commission (SEC). Another article by TheStreet.com alleged that
although the Company was initially describing its PV-10 oncology drug as
a “breakthrough” drug for skin cancer on its website, the description of
the drug was later amended to “investigational.” Since the release of
these two articles, PVCT shares have dropped over 24%.
If you currently own common stock in Provectus Biopharmaceuticals, Inc.,
have any information to assist in our investigation, or have questions
or concerns regarding this notice or your rights or interests in this
matter, please contact Federman & Sherwood. Federman & Sherwood has
extensive nationwide experience in representing investors in securities,
derivative and merger-related shareholder class actions, and has been
appointed as lead counsel in multiple complex cases across the country.
Copyright Business Wire 2014